Vedolizumab in early and late Crohn’s disease (LOVE-CD): a phase 4 open-label cohort study
Lancet Gastroenterology & Hepatology 2026; 11:12–21 Epub ahead of print Doi: 10.1016/S2468-1253(25)00233-X.
D’Haens et al. evaluated the effectiveness and safety of vedolizumab in inducing and maintaining deep remission in patients with early versus late Crohn’s disease in the Phase 4 LOVE-CD study.